pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$BMYBRISTOL MYERS SQUIBB CO

$BMY61.35-2.51%
Princeton, NJ, USupdated 1d ago

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multip

read more…

SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval166 co-mentions · 83 sources
  • drugOPDIVO166 co-mentions · 83 sources
  • drugOPDIVO QVANTIG166 co-mentions · 83 sources
  • drugnivolumab166 co-mentions · 83 sources
  • company$CELG-RIBRISTOL MYERS SQUIBB CO84 co-mentions · 84 sources
  • tagDrug Shortage1 co-mentions · 1 sources
  • drugazacitidine1 co-mentions · 1 sources
  • drugOnureg1 co-mentions · 1 sources
pipeline
3
marketed
0
phase 3
0
catalysts ytd
6
approvals ytd
2
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Unknown: 3
3Unknown
drug
INREBIC
1 INDICATIONS AND USAGE INREBIC ® is indicated for the tr…
Tyrosine-protein kinase JAK2Receptor-type tyrosine-protein kinase FLT3
drug
OPDIVO
1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination o…
Programmed cell death protein 1
drug
OPDIVO QVANTIG
1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination o…
Programmed cell death protein 1

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Oct 29, 2026
earnings
$BMY61.35-2.51%
20d ago
BRISTOL MYERS SQUIBB CO earnings
BRISTOL MYERS SQUIBB CO
→
view all catalysts →
🐶 Hiring Signal
631 open roles at BRISTOL MYERS SQUIBB CO →

Where BRISTOL MYERS SQUIBB CO is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaCNS / Neuroscience 55Oncology 53Cardiovascular 31Immunology & Inflammation 15Hematology 3Respiratory 1
departmentIT & Engineering 69R&D / Discovery 60Commercial 37Medical Affairs 31Manufacturing / CMC 28Quality 24

News

  • CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions
    At the Clinical Trials on Alzheimer’s Disease Conference, BMS finally revealed early data for its Alzheimer’s disease psychosis trials of KarXT, marketed as Cobenfy in schizophrenia.
    biospace · 6h ago
  • CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
    Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…
    biospace · 6h ago
  • Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
    The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
    biopharma_dive · 6h ago
  • Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
    Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.
    biospace · 7h ago
  • Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
    The Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.
    biospace · 8h ago
  • Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
    Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
    biospace · 10h ago
  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…
    biospace · 12h ago
  • AI drugmaker Isomorphic restocks with $5B fundraise
    Even as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.
    biopharma_dive · 1d ago
  • AstraZeneca, Calidi, Tempest make significant workforce cuts
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 1d ago
  • CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy
    At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease.
    biospace · 1d ago
view all news mentions →
identifiers
ticker
$BMY
SEC CIK
0000014272
country
US
source
sec_tickers
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 34m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?